Clinical trial • Oncology|Haematology
Clinical trial in Relapsed and refractory acute myeloid leukaemia (AML)|Myelodysplastic syndrome (MDS)
Clinical trial for Relapsed and refractory acute myeloid leukaemia (AML)|Myelodysplastic syndrome (MDS). 26 participants.
Overview
- Trial Therapeutic Area
- Oncology|Haematology
- Trial Disease
- Relapsed and refractory acute myeloid leukaemia (AML)|Myelodysplastic syndrome (MDS)
Key dates
- Initial CTIS Submission Date
- 24-08-2025
- First CTIS Authorization Date
- 19-01-2026
Trial design
Clinical trial across 2 sites in Sweden.
- Target Sample Size
- 26
Eligibility
Recruits 26 No vulnerable populations selected (populationOfTrialSubjects.isVulnerablePopulationSelected = false); consent or assent process not specified in the provided record..
- Vulnerable Population
- No vulnerable populations selected (populationOfTrialSubjects.isVulnerablePopulationSelected = false); consent or assent process not specified in the provided record.
Recruitment
- Planned Sample Size
- 26
- Recruitment Window Months
- 72
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 26
Sweden
- Earliest CTIS Part Ii Submission Date
- 10-11-2025
- Latest Decision Or Authorization Date
- 19-01-2026
- Processing Time Days
- 70
- Number Of Sites
- 2
- Number Of Participants
- 26
Sites
- Site Name
- Karolinska University Hospital
- Department Name
- CAST
- Principal Investigator Name
- Andreas Björklund
- Principal Investigator Email
- andreas.bjorklund@regionstockholm.se
- Contact Person Name
- Andreas Björklund
- Contact Person Email
- andreas.bjorklund@regionstockholm.se
- Site Name
- Uppsala University Hospital
- Department Name
- Hematology
- Principal Investigator Name
- Daniel Moreno Berggren
- Principal Investigator Email
- daniel.berggren@akademiska.se
- Contact Person Name
- Daniel Moreno Berggren
- Contact Person Email
- daniel.berggren@akademiska.se
Sponsor
Primary sponsor
- Full Name
- Karolinska Institutet
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Sweden
Related trials
Other published trials that may interest you.
- DAUNORUBICIN HYDROCHLORIDE for Acute myeloid leukemia|Relapsed or refractory acute myeloid leukemia
- Brentuximab vedotin for Peripheral T-cell lymphoma (PTCL) | Anaplastic large cell lymphoma (ALCL) | Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) | Angioimmunoblastic T-cell lymphoma (AITL) | Adult T-cell leukaemia/lymphoma (ATLL) | Enteropathy-associated T-cell lymphoma (EATL) | Hepatosplenic T-cell lymphoma | Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) | Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract | Follicular T-cell lymphoma | Nodal peripheral T-cell lymphoma with T-follicular helper phenotype
- RITUXIMAB for Diffuse large B-cell lymphoma (ABC)
- Lenalidomide for Primary central nervous system lymphoma
- Cytarabine; Daunorubicin for Myelodysplastic syndrome (higher-risk)|Oligoblastic acute myeloid leukaemia (AML)